Navigation Links
MGI Pharma, Inc. Summarizes Data Presented at the 2007 American,Society of Clinical Oncology (ASCO) Annual Meeting

of Days 2-5, and during the overall period of Days 1-5. On Day 1, 100% of patients had no emesis and at least 95% of patients had no emetic episodes in the delayed and overall time periods. A complete response was demonstrated in 75% of patients on Day 1 and in 67% of patients in the delayed time period. Based on VAS, the majority of patients had no significant nausea in the acute, delayed or overall phases. The most commonly observed adverse events were headache and fatigue.

Phase 3 Results of Aloxi in Pediatric Patients

The results of a phase 3, multicenter, randomized, double-blind study to assess the safety, efficacy and pharmacokinetics of single intravenous doses of Aloxi in pediatric patients were presented in a poster session on Sunday, June 3, 2007. Sixty patients (2-17 years of age) were randomized to receive either 3 mcg/kg or 10 mcg/kg with a maximum total dose of 0.25 mg and 0.75mg, respectively, prior to moderately (n=21) or highly (n=39) emetogenic chemotherapy. Twelve additional patients, age 28 days-23 months, were studied in open-label design at the same doses. The majority of patients had received previous chemotherapy. Day 1 complete response (CR: no emetic episodes and no rescue medication) rates of 37.1% (CI, 22.0-55.1%) and 54.1% (CI, 37.1-70.2%) were reported in the 3 mcg/kg (n=35) and 10 mcg/kg (n=37) groups, respectively. The percentage of patients who were emesis-free was numerically higher in the 10 mcg/kg group; however, as with CR, these differences were primarily seen in children less than 2 years. A numerically higher proportion of patients (aged 6-17 years) with no nausea was also observed in the 10 mcg/kg group. Both doses showed a similar time to treatment failure (time to first emetic episode and/or first administration of rescue medication). The pharmacokinetic data show that total body clearance and volume of distribution of Aloxi increased with age-related body weight, as expected. The long half-life (21-37 hours
'"/>




Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
5. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
8. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
9. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
10. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
11. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
Post Your Comments:
(Date:7/11/2014)... 2014 According to a ... of Material, Application (Healthcare, Homeland security, Industrial application, ... Instrument, Hand-Held Instruments, Fixed, and Installed Instruments) & ... published by MarketsandMarkets, the Scintillator Market is expected ... 2014 to 2020, and reach $479.16 Million in ...
(Date:7/11/2014)... -- Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: ... via a placement of A$16.3 million to institutional investors ... Asia and Australia ... (SPP) to be offered to existing shareholders.  The placement ... "This capital raising positions us strongly to ...
(Date:7/11/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) has ... Testing Market - Forecasts to 2019: Expected to ... is expected to be valued at USD 4,943.0 ... http://photos.prnewswire.com/prnh/20130307/600769 The ... according to immunoprotein types which include immunoglobulins, complement ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... , NEW YORK, ... market research report is available in its catalogue: ... Pharmaceuticals - Current and Future Market Outlook, Regulatory ... , Summary , The author ...
... , NEWNAN, ... specialty surface treatments for medical devices and of specialty implants, ... Gordy, will give an opening address for the Technology Parade ... Israel. "We must leave the era of petty self-interest ...
Cached Medicine Technology:Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 2Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 3Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 4Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 5Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 6Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 7Reportlinker Adds Direct to Consumer (DTC) Advertising in Pharmaceuticals - Current and Future Market Outlook, Regulatory Landscape and Case Studies 8CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices 2
(Date:7/14/2014)... (PRWEB) July 14, 2014 The governments ... investment in the Global Mobile Health Solutions market. For ... the Health IT for Economic and Clinical Health Act ... 2009. , Analysts forecast the Global Mobile Health ... 34.88 percent over the period 2013-2018. According to the ...
(Date:7/14/2014)... July 14, 2014 The report ... Services [Physical Security, Life Safety, Facility Management], IT ... Forecast & Analysis (2014 - 2019)” defines and ... an in-depth analysis and forecasting of revenues. The ... various restraints and opportunities impacting it, along with ...
(Date:7/14/2014)... fitness may buffer some of the adverse health effects ... by researchers from the American Cancer Society, The Cooper ... in the journal Mayo Clinic Proceeding s, and ... and blood markers associated with cardiovascular disease is markedly ... behavior has been linked to an increase risk of ...
(Date:7/14/2014)... 14, 2014 This report provides ... in Americas. The analysis includes market size data ... and key company share data by revenue in ... and Mexico. It uses data and information sourced ... in-house analysis. , Scope,     Information ...
(Date:7/14/2014)... 2014 Secure Decisions, a leading provider ... with the Software Assurance Marketplace (SWAMP) to build a ... that drives everyday life. , The SWAMP, implemented by ... the Morgridge Institute for Research, is funded by the ... security practices by building a free facility with a ...
Breaking Medicine News(10 mins):Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 2Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 3Health News:Mobile Health Solutions Market to Grow at 34.88% CAGR by 2018, Says a New Research Report at Sandlerresearch.org 4Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 2Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 3Health News:Americas Transcatheter Heart Valves Market 2020 Forecasts in New Research Report at LifeScienceIndustryResearch.com 4Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3
... and Willing to ... 20s, - Boomers Can Stay On-the-Go with New ThermaCare(R) Arthritis HeatWraps ... percent of baby boomers claim they feel an average of 11 ... they are more,adventurous and willing to experiment now than when they ...
... guided trial design may increase probability of tumor response ... and accelerates ... (Nasdaq and MTAX: CTIC) and Systems Medicine, LLC (SM), a,wholly-owned ... to its complete phase Ib trial of brostallicin used in ...
... CARLSBAD, Calif., Oct. 18 Isis,Pharmaceuticals, Inc. (Nasdaq: ... added a,new diabetes drug targeting the sodium dependent ... ISIS 388626, a generation 2.2,antisense drug that acts ... existing pipeline of drugs in development for the,treatment ...
... Lighted slippers for,those with troubled eyesight. A ... the player,s motions. Bowling equipment for those with ... One-stop online shopping for older adults and ... easier at Rehability! Your Optimal Living,Store, http://www.rehabilitystores.com ...
... Oct. 18 More than half of holiday shoppers ... to a good cause*. This,year, choose a gift that ... Alzheimer,s disease, the seventh leading cause of death,in the ... services for families struggling with,Alzheimer,s or support innovative research ...
... at US$26.00 Per Share -, VICTORIA, Oct. ... ; TSX: ASV) today announced that it has ... GALN) under which,Galenica, through a wholly-owned Canadian subsidiary, ... price of US$26.00 per share in cash. The,total ...
Cached Medicine News:Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 2Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 3Health News:Forget the 'Old' Stereotypes - New Survey Reveals that Baby Boomers Are Feeling More 'Young' and Active than Ever! 4Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 2Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 3Health News:U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors 4Health News:Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes 2Health News:Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes 3Health News:Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes 4Health News:Holiday Gifts for Those With Disabilities & Other Special Needs 2Health News:Holiday Gifts That Help Fight Alzheimer's Disease 2Health News:Aspreva to be Acquired by Galenica For US$915 Million 2Health News:Aspreva to be Acquired by Galenica For US$915 Million 3Health News:Aspreva to be Acquired by Galenica For US$915 Million 4Health News:Aspreva to be Acquired by Galenica For US$915 Million 5
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... ThumbFit™ reduces joint instability without disturbing ... remarkably comfortable and easy for users ... CHT and Robert V. Sypher Jr., ... in response to patients' complaints of ...
... the MP joint and the CMC joint of the ... both of the thumb joints. An excellent choice for ... who need maximum mobility for daily activities. Ideal for ... and for those with pain due to repetitive stress. ...
... molded from rigid plastic in a distinctive design ... comfort. The uniquely sculpted distal trim line ... maximum function of the hand. This is ... and sprains of the MCP joint, basal joint ...
Medicine Products: